Veracyte Has Released Our Inaugural ESG Report Read More
Search Open Mobile Menu
Veracyte Has Released Our Inaugural ESG Report Read More

Veracyte® Investor Relations

Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
- Three abstracts demonstrate new insights that can be derived from whole-transcriptome-based thyroid cancer molecular profiles - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 21, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s
Toggle Summary Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 7, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine , Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France .


There are currently no events to display.


Title Documents

Corporate Presentation September 2023